Clinical Trials Browser

INDUSTRY × Recurrence × inebilizumab × Clear all

NCT02271945 2018-03-12

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Phase 1/2 Completed

10 enrolled 17 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT01466153 2017-05-31

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

183 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell